Skip to main content
Publish date:

Jim Cramer: Focus on Valeant's Debt Load

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer urges investors to look under the hood of Valeant Pharmaceuticals' latest earnings report.
Author:

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer urges investors to look under the hood of Valeant Pharmaceuticals' (VRX) latest earnings report. 

"When Valeant reported, the headline numbers were good and the stock jumped a dollar," Cramer said, adding that investors should look deeper into the report, as Valeant's debt load is worrisome.

TheStreet Recommends